Answer
Bexsero stimulates bactericidal antibodies against NHBA, NadA, fHbp and PorA P1.4, which are expected to protect against invasive meningococcal disease by killing strains expressing these antigens at sufficient levels.
Sources for this answer
- Bexsero Meningococcal Group B vaccine for injection in pre-filled syringeGlaxoSmithKline UK · emc · SmPC §5.1 Pharmacodynamic properties · Version 25Document updated
Sources checked